2024-09-06 - Analysis Report
## Gilead Sciences, Inc. (GILD) Stock Analysis Report

**Company Overview:** Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines in areas of unmet medical need, including HIV/AIDS, oncology, inflammation, and liver diseases.

**Performance Analysis:**

**1. Relative Performance:** 

* **Cumulative Return:** GILD has returned 14.61% compared to the S&P 500 (VOO) which returned 84.86%. This puts GILD significantly behind the market.
* **Relative Strength (vs. S&P 500):** The current relative strength is -75.15%, meaning GILD's performance has been 75.15% lower than the S&P 500. This places GILD within the 15.83rd percentile of its historical performance relative to the index.  This indicates a relatively weak performance compared to the broader market. 

**2. Recent Price Movement:**

* **Closing Price:** $79.13
* **5-Day Moving Average:** $79.17
* **20-Day Moving Average:** $75.96
* **60-Day Moving Average:** $72.28

GILD's price has been relatively stable over the past few weeks, trading slightly above its 5-day moving average. The price is also moving closer to its 20-day and 60-day moving averages, suggesting potential consolidation.

**3. Technical Indicators:**

* **RSI:** 80.61. This indicates that the stock is currently in overbought territory.
* **PPO:** 0.36. This suggests that the stock is experiencing strong momentum.
* **Delta_Previous_Relative_Divergence:** -5.9. This indicates a slight decrease in relative strength compared to the previous period. 
* **Expected_Return:** 21.27%. This represents the expected return over the next 5 years for a current investment.

**4. Recent Earnings and Outlook:**

| Date       | EPS      | Revenue  | 
|-----------|----------|----------|
| 2024-08-08 | 1.29     | 6.95 B$  |
| 2024-05-08 | -3.34    | 6.69 B$  |
| 2023-11-07 | 1.75     | 7.05 B$  |
| 2023-08-04 | 0.84     | 6.60 B$  |
| 2024-08-08 | 0.84     | 6.60 B$  |

The most recent earnings (2024-08-08) beat estimates. However, the company has faced some volatility in earnings over the past few quarters, highlighting the challenges in managing its business.

**Overall Analysis:**

GILD is currently experiencing a period of price stability, but its performance has lagged behind the overall market. The company's recent earnings have been mixed, and its technical indicators point to potential overbought conditions. This suggests that while GILD may offer potential for growth, it may be best to approach the stock with caution.

**Disclaimer:** This is just an analysis based on the given data and should not be interpreted as financial advice. Investors should conduct their own research and consult with a qualified professional before making any investment decisions. 
